FEATURED

Live IASLC 2017 Coverage

Follow our ongoing coverage of the IASLC 18th World Conference on Lung Cancer (WCLC) in Yokohama, Japan.

Adjuvant Therapy in Renal Cell Carcinoma

About one-third of patients will experience disease recurrence after undergoing nephrectomy, and clinical trials exploring the use of adjuvant therapy in these patients produce conflicting results.

Ipilimumab and Nivolumab for Metastatic Melanoma

Mario Sznol, MD, discusses melanoma clinical trial results just published in the Journal of Clinical Oncology.

Fact Sheet: Ginkgo Biloba and Cancer

The available human studies do not support the role of Ginkgo biloba as a treatment for cancer, but the published studies were not placebo-controlled, making it difficult to draw conclusions from the data.

First-line Treatment Selection in Melanoma

Ongoing trials, including those that combine immunotherapy with BRAF inhibitors or a triple combination of an anti-PD-1 antibody with BRAF and MEK inhibitors, may provide more options to patients.

Pazopanib: Adjuvant Therapy in Localized RCC

While renal cell carcinoma treatment continue to improve, it's unclear whether pazopanib should be used in the adjuvant setting.

Fact Sheet: St John’s Wort, Cancer

In vivo studies suggest that extracts of St John's wort may have apoptotic effects on cancer cells, but human studies have not been conducted to test this hypothesis.

CAR-T Immunotherapy, Hopes for Treatment

The high cost of CAR-T therapy concerns patient advocates who worry about the "financial toxicity" implications for patients and their families. But these cancer immunotherapies might offer an excellent value for clinical oncology, proponents claim.

Hurricane Aftermath Tests Cancer Centers

Hurricanes Harvey, Irma, and Maria battered Texas, Florida, and Puerto Rico in quick succession, and the ensuing floods tested cancer centers' preparation efforts and continuity of care, officials told Cancer Therapy Advisor.

Fact Sheet: Vitamin E and Cancer

Vitamin E supplementation appears to reduce the risk of chemotherapy-induced neurotoxicity and several radiation-induced toxicities, though one study found increased recurrence rates with its use.

CPN for Pancreatic Cancer-associated Pain

Pain management continues to be a challenge for patients with pancreatic cancer, though CPN may provide significant pain relief and an opportunity to reduce the amount of required narcotics.

Paul Bunn, MD: ESMO 2017 Congress

Paul Bunn, Jr, MD, distinguished professor in the division of medical oncology and James Dudley chair of lung cancer research at the University of Colorado, Denver, discusses important lung cancer research presented at the ESMO 2017 Congress.

Ask The Experts: Treating Sarcoma

Cancer Therapy Advisor interviewed 3 experts about how to best treat sarcoma.

Explore a combination therapy

Read about a triplet-based therapy for multiple myeloma patients who have received at least one prior treatment.

In ER+, early-stage breast cancer

Individualizing treatment with extended adjuvant endocrine therapy

For the treatment of metastatic non-small

Biomarker testing for epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations is important when considering a first-line therapy

Looking for a Job?

Access our job board to view over 1,​200 job openings throughout the US.

Treatment Regimens

A full listing of cancer treatment and drug information is available to access.

In ER+, early-stage breast cancer

Experts discuss risk vs benefit of extended adjuvant endocrine therapy

Explore a combination therapy

Read about a triplet-based therapy for multiple myeloma patients who have received at least one prior treatment.

Latest Features

Adjuvant Therapy in Renal Cell Carcinoma: Still Riddled With Unknowns

Adjuvant Therapy in Renal Cell Carcinoma: Still Riddled With Unknowns

About one-third of patients will experience disease recurrence after undergoing nephrectomy, and clinical trials exploring the use of adjuvant therapy in these patients produce conflicting results.

Long-term Survival From Ipilimumab/Nivolumab Combination in Metastatic Melanoma

Long-term Survival From Ipilimumab/Nivolumab Combination in Metastatic Melanoma

Mario Sznol, MD, of the Yale University School of Medicine in New Haven, Connecticut, discusses melanoma clinical trial results just published in the Journal of Clinical Oncology.

Questions Remain for First-line Treatment Selection and Sequencing in Advanced Melanoma

Questions Remain for First-line Treatment Selection and Sequencing in Advanced Melanoma

Ongoing trials, including those that combine immunotherapy with BRAF inhibitors or a triple combination of an anti-PD-1 antibody with BRAF and MEK inhibitors, may provide more options to patients.

Pazopanib: Where Does It Stand as Adjuvant Therapy in Localized RCC?

Pazopanib: Where Does It Stand as Adjuvant Therapy in Localized RCC?

While renal cell carcinoma treatment continue to improve, it's unclear whether pazopanib should be used in the adjuvant setting.

Arrival of CAR-T Immunotherapy Raise Hopes for Treatment and Anxieties About Costs

Arrival of CAR-T Immunotherapy Raise Hopes for Treatment and Anxieties About Costs

The high cost of CAR-T therapy concerns patient advocates who worry about the "financial toxicity" implications for patients and their families. But these cancer immunotherapies might offer an excellent value for clinical oncology, proponents claim.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters